Biotechnology Industry Organization v. District of Columbia
United States Court of Appeals for the Federal Circuit
496 F.3d 1362 (2007)
- Written by Mary Phelan D'Isa, JD
Facts
The District of Columbia enacted legislation prohibiting any patented drug from being sold in the district for an excessive price. Excessive price was not expressly defined in the statute, but a rebuttable presumption of such was recognized if the wholesale price was more than 30 percent higher than the comparable price in any high-income country. Two industry organizations—Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization (plaintiffs)—filed separate suits challenging the law as an illegal price control in violation of federal patent laws. The district court consolidated the cases and concluded that the law was preempted by the federal patent laws and enjoined its enforcement. The district appealed.
Rule of Law
Issue
Holding and Reasoning (Gajarsa, J.)
Dissent (Dyk, J.)
What to do next…
Here's why 832,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,500 briefs, keyed to 994 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.
